- Home
- JUNS vs DMAC Comparison
JUNS vs DMAC Comparison
Compare JUNS & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JUNS
- DMAC
- Stock Information
- Founded
- JUNS 2015
- DMAC 2000
- Country
- JUNS United States
- DMAC United States
- Employees
- JUNS N/A
- DMAC N/A
- Industry
- JUNS
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- JUNS
- DMAC Health Care
- Exchange
- JUNS NYSE
- DMAC Nasdaq
- Market Cap
- JUNS 20.5M
- DMAC 178.0M
- IPO Year
- JUNS 2024
- DMAC N/A
- Fundamental
- Price
- JUNS $1.46
- DMAC $3.76
- Analyst Decision
- JUNS
- DMAC Strong Buy
- Analyst Count
- JUNS 0
- DMAC 2
- Target Price
- JUNS N/A
- DMAC $8.00
- AVG Volume (30 Days)
- JUNS 998.6K
- DMAC 307.4K
- Earning Date
- JUNS 08-11-2025
- DMAC 08-06-2025
- Dividend Yield
- JUNS N/A
- DMAC N/A
- EPS Growth
- JUNS N/A
- DMAC N/A
- EPS
- JUNS N/A
- DMAC N/A
- Revenue
- JUNS N/A
- DMAC N/A
- Revenue This Year
- JUNS N/A
- DMAC N/A
- Revenue Next Year
- JUNS N/A
- DMAC N/A
- P/E Ratio
- JUNS N/A
- DMAC N/A
- Revenue Growth
- JUNS N/A
- DMAC N/A
- 52 Week Low
- JUNS $0.51
- DMAC $2.80
- 52 Week High
- JUNS $19.51
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- JUNS N/A
- DMAC 47.18
- Support Level
- JUNS N/A
- DMAC $3.48
- Resistance Level
- JUNS N/A
- DMAC $3.99
- Average True Range (ATR)
- JUNS 0.00
- DMAC 0.32
- MACD
- JUNS 0.00
- DMAC -0.00
- Stochastic Oscillator
- JUNS 0.00
- DMAC 41.01
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.